160 related articles for article (PubMed ID: 22955878)
1. Tumour necrosis factor-alpha inhibitor-induced hepatic injury in patients with rheumatoid arthritis: two case reports and an analysis of the laboratory data from the Slovenian national biologicals registry.
Perdan-Pirkmajer K; Hočevar A; Rotar Ž; Žibert J; Marolt VF; Gučev F; Tomšič M
Rheumatol Int; 2013 Nov; 33(11):2885-8. PubMed ID: 22955878
[TBL] [Abstract][Full Text] [Related]
2. Risk and severity of herpes zoster in patients with rheumatoid arthritis receiving different immunosuppressive medications: a case-control study in Asia.
Liao TL; Chen YM; Liu HJ; Chen DY
BMJ Open; 2017 Jan; 7(1):e014032. PubMed ID: 28057661
[TBL] [Abstract][Full Text] [Related]
3. [Malignancy and tumor necrosis factor inhibitors in juvenile idiopathic arthritis].
Horneff G
Z Rheumatol; 2010 Aug; 69(6):516-26. PubMed ID: 20532787
[TBL] [Abstract][Full Text] [Related]
4. Comparative effectiveness of tumour necrosis factor alpha inhibitors in combination with either methotrexate or leflunomide.
Strangfeld A; Hierse F; Kekow J; von Hinueber U; Tony HP; Dockhorn R; Listing J; Zink A
Ann Rheum Dis; 2009 Dec; 68(12):1856-62. PubMed ID: 19126559
[TBL] [Abstract][Full Text] [Related]
5. Risk of elevated liver enzymes associated with TNF inhibitor utilisation in patients with rheumatoid arthritis.
Sokolove J; Strand V; Greenberg JD; Curtis JR; Kavanaugh A; Kremer JM; Anofrei A; Reed G; Calabrese L; Hooper M; Baumgartner S; Furst DE;
Ann Rheum Dis; 2010 Sep; 69(9):1612-7. PubMed ID: 20448284
[TBL] [Abstract][Full Text] [Related]
6. A systematic review of the effectiveness of adalimumab, etanercept and infliximab for the treatment of rheumatoid arthritis in adults and an economic evaluation of their cost-effectiveness.
Chen YF; Jobanputra P; Barton P; Jowett S; Bryan S; Clark W; Fry-Smith A; Burls A
Health Technol Assess; 2006 Nov; 10(42):iii-iv, xi-xiii, 1-229. PubMed ID: 17049139
[TBL] [Abstract][Full Text] [Related]
7. Comparative effectiveness of first-line biological monotherapy use in rheumatoid arthritis: a retrospective analysis of the RECord-linkage On Rheumatic Diseases study on health care administrative databases.
Silvagni E; Bortoluzzi A; Carrara G; Zanetti A; Govoni M; Scirè CA
BMJ Open; 2018 Sep; 8(9):e021447. PubMed ID: 30206082
[TBL] [Abstract][Full Text] [Related]
8. Tumor necrosis factor-α antagonist therapy for concomitant rheumatoid arthritis and hepatitis C virus infection: a case series study.
Lin KM; Cheng TT; Lin JC; Chen CJ
Clin Rheumatol; 2015 Jun; 34(6):1039-46. PubMed ID: 25939523
[TBL] [Abstract][Full Text] [Related]
9. Lipid profile of rheumatoid arthritis patients treated with anti-tumor necrosis factor-alpha drugs changes according to disease activity and predicts clinical response.
Cacciapaglia F; Anelli MG; Rinaldi A; Serafino L; Covelli M; Scioscia C; Iannone F; Lapadula G
Drug Dev Res; 2014 Nov; 75 Suppl 1():S77-80. PubMed ID: 25381986
[TBL] [Abstract][Full Text] [Related]
10. Secondary syphilis following tumor necrosis factor-α inhibitor treatment for rheumatoid arthritis.
Asahina A; Ishii N; Tohma S
J Dermatol; 2012 Feb; 39(2):199-201. PubMed ID: 21463364
[No Abstract] [Full Text] [Related]
11. The persistence of golimumab compared to other tumour necrosis factor-α inhibitors in daily clinical practice for the treatment of rheumatoid arthritis, ankylosing spondylitis and psoriatic arthritis: observations from the Slovenian nation-wide longitudinal registry of patients treated with biologic disease-modifying antirheumatic drugs-BioRx.si.
Rotar Ž; Tomšič M; Praprotnik S;
Clin Rheumatol; 2019 Feb; 38(2):297-305. PubMed ID: 30324406
[TBL] [Abstract][Full Text] [Related]
12. Survival of TNF-alpha antagonists in rheumatoid arthritis: a long-term study.
Markatseli TE; Alamanos Y; Saougou I; Voulgari PV; Drosos AA
Clin Exp Rheumatol; 2012; 30(1):31-8. PubMed ID: 22153557
[TBL] [Abstract][Full Text] [Related]
13. Golimumab in patients with active rheumatoid arthritis after treatment with tumour necrosis factor alpha inhibitors (GO-AFTER study): a multicentre, randomised, double-blind, placebo-controlled, phase III trial.
Smolen JS; Kay J; Doyle MK; Landewé R; Matteson EL; Wollenhaupt J; Gaylis N; Murphy FT; Neal JS; Zhou Y; Visvanathan S; Hsia EC; Rahman MU;
Lancet; 2009 Jul; 374(9685):210-21. PubMed ID: 19560810
[TBL] [Abstract][Full Text] [Related]
14. Long-term efficacy and safety of add-on tacrolimus for persistent, active rheumatoid arthritis despite treatment with methotrexate and tumor necrosis factor inhibitors.
Naniwa T; Iwagaitsu S; Kajiura M
Int J Rheum Dis; 2018 Mar; 21(3):673-687. PubMed ID: 29314738
[TBL] [Abstract][Full Text] [Related]
15. Real-world Effectiveness of Biologic Disease-modifying Antirheumatic Drugs for the Treatment of Rheumatoid Arthritis After Etanercept Discontinuation in the United Kingdom, France, and Germany.
Li N; Betts KA; Messali AJ; Skup M; Garg V
Clin Ther; 2017 Aug; 39(8):1618-1627. PubMed ID: 28729087
[TBL] [Abstract][Full Text] [Related]
16. Elevated liver enzyme tests among patients with rheumatoid arthritis or psoriatic arthritis treated with methotrexate and/or leflunomide.
Curtis JR; Beukelman T; Onofrei A; Cassell S; Greenberg JD; Kavanaugh A; Reed G; Strand V; Kremer JM
Ann Rheum Dis; 2010 Jan; 69(1):43-7. PubMed ID: 19147616
[TBL] [Abstract][Full Text] [Related]
17. Lack of adverse effect of anti-tumor necrosis factor-α biologics in treatment of rheumatoid arthritis: 5 years follow-up.
Dewedar AM; Shalaby MA; Al-Homaid S; Mahfouz AM; Shams OA; Fathy A
Int J Rheum Dis; 2012 Jun; 15(3):330-5. PubMed ID: 22709496
[TBL] [Abstract][Full Text] [Related]
18. Two-year persistence of golimumab as second-line biologic agent in rheumatoid arthritis as compared to other subcutaneous tumor necrosis factor inhibitors: real-life data from the LORHEN registry.
Favalli EG; Sinigaglia L; Becciolini A; Grosso V; Gorla R; Bazzani C; Atzeni F; Sarzi Puttini PC; Fusaro E; Pellerito R; Caporali R
Int J Rheum Dis; 2018 Feb; 21(2):422-430. PubMed ID: 29082659
[TBL] [Abstract][Full Text] [Related]
19. Use of leflunomide plus TNF-α inhibitors in rheumatoid arthritis.
Murdaca G; Spanò F; Puppo F
Expert Opin Drug Saf; 2013 Nov; 12(6):801-4. PubMed ID: 23889669
[TBL] [Abstract][Full Text] [Related]
20. Increased levels of rheumatoid factors after TNF inhibitor in rheumatoid arthritis.
Mendonça JA; Marques-Neto JF; Samara AM; Appenzeller S
Rheumatol Int; 2012 Mar; 32(3):815-8. PubMed ID: 21327431
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
